Last reviewed · How we verify
Pantoprazole (Pantoloc)
Pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Pantoprazole (Pantoloc) |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Hypomagnesemia
Key clinical trials
- Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease (PHASE4)
- Phototoxicity of Frequently Prescribed Medicines (NA)
- Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG (PHASE4)
- Stress Ulcer Prophylaxis in the Intensive Care Unit (PHASE4)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
- Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications (PHASE4)
- Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers (PHASE4)
- Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantoprazole (Pantoloc) CI brief — competitive landscape report
- Pantoprazole (Pantoloc) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI